Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 62Carcinoma, Hepatocellular 25Neoplasm Metastasis 15Rectal Neoplasms 11Colonic Neoplasms 10Gastrointestinal Stromal Tumors 9Sarcoma 6Ovarian Neoplasms 5Osteosarcoma 5Glioblastoma 5Cholangiocarcinoma 5Stomach Neoplasms 4Melanoma 4Liver Neoplasms 4Sarcoma, Ewing 3Pancreatic Neoplasms 3Neoplasms 3Leukemia, Myeloid, Acute 3Esophageal Neoplasms 3Colorectal Cancer Metastatic 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Rhabdomyosarcoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Mesothelioma, Malignant 2Lymphoma, Non-Hodgkin 2Hematologic Neoplasms 2Hemangiosarcoma 2Gastrointestinal Neoplasms 2

Interventions

regorafenib 1Photochemotherapy 1Cholangiopancreatography, Endoscopic Retrograde 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Bile Duct Diseases × regorafenib × Clear all
NCT02115542 2021-10-12

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
39 enrolled 11 charts
Gastrointestinal

Bile Duct Diseases, Bile Duct Neoplasms, Carcinoma, Gallbladder Diseases, Gallbladder Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡